Oncolytics Biotech reported that pelareorep combined with atezolizumab achieved a median response duration of about 15 months in second-line anal cancer patients, surpassing the 9.5 months seen with existing FDA-approved therapies. All responding patients survived beyond one year, with some over two years, indicating enhanced clinical benefits in HPV-driven cancers. The FDA has granted Fast Track designation, supporting potential accelerated approval and expansion into HPV-related head and neck cancers. Oncolytics plans further clinical studies to advance pelareorep as a backbone immunotherapy across multiple HPV-associated cancers.
Oncolytics Biotech's recent data on pelareorep offers context for readers. Among 150 health-sector US stocks on Pluang, 75 rose and 69 fell today. Notable moves include Illumina (ILMN) at USD 275.39, up 1.60%, Medline (MDLN) at USD 33.15, down 1.60%, and 10X Genomics (TXG) at USD 74.10, up 1.56% with 95% sell activity, as of Oct 27, 2026 19:51 WIB.
Black Ore introduced Black Ore for Small Firms, an AI-powered tax automation platform designed for small to mid-sized accounting practices. It integrates with Intuit tax software, enabling firms to handle more clients without increasing staff by auto...
Alm. Brand A/S executed a share buy-back program from October 20 to 26, 2026, purchasing 1.81 million shares at an average price of DKK 17.41 each. This brings the total shares bought under the program to nearly 19.58 million, costing about DKK 324 m...
Hyphenate, an autonomous finance platform, secured $45 million in Series A funding following an 86-fold revenue increase and an 11-fold growth in customers over 12 months. Its AI-driven agents now handle 90% of routine finance work, such as invoicing...
CareCloud has named Mitchell Brie as Chief Compliance Officer to lead its growing healthcare compliance business. Brie, founder of Empower Healthcare & Compliance Partners (acquired by CareCloud), will oversee corporate compliance and continue as Pre...
Man Group PLC has publicly disclosed holding a 5.64% interest in Vesuvius plc, including direct shares and cash-settled derivatives. This disclosure is related to an ongoing offer involving RHI Magnestia N.V., which is also named in the filing. The d...
